Juha E K Hartikainen
Overview
Explore the profile of Juha E K Hartikainen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lappalainen A, Hartikainen J, Teppo K, Halminen O, Aro A, Siponen R, et al.
Int J Cardiol Heart Vasc
. 2024 Nov;
55:101541.
PMID: 39507295
Background: Catheter ablation is a well-established treatment to prevent atrial fibrillation (AF) and atrial flutter (AFL) recurrences and to relieve symptoms, whereas pacemaker implantation and atrioventricular node (AVN) ablation is...
2.
Leikas A, Hartikainen J, Kastrup J, Mathur A, Gyongyosi M, Fernandez-Aviles F, et al.
Open Heart
. 2024 Oct;
11(2).
PMID: 39424303
Background: Despite tremendous therapeutic advancements, a significant proportion of coronary artery disease patients suffer from refractory angina pectoris, that is, quality-of-life-compromising angina that is non-manageable with established pharmacological and interventional...
3.
Koskelo J, Lehmusaho A, Laitinen T, Hartikainen J, Lahtinen T, Leino T, et al.
Appl Ergon
. 2024 Aug;
121:104370.
PMID: 39186837
Understanding the operator's cognitive workload is crucial for efficiency and safety in human-machine systems. This study investigated how cognitive workload modulates cardiac autonomic regulation during a standardized military simulator flight....
4.
Vartiainen N, Hartikainen J, Laitinen T, Kuikka P, Mussalo H, Laitinen T
Eur Heart J Imaging Methods Pract
. 2024 Jul;
2(1):qyae010.
PMID: 39045203
Aims: Endothelial dysfunction is a systemic disorder and risk factor for atherosclerosis. Our aim was to assess whether there is a relation between peripheral endothelial function and myocardial perfusion in...
5.
Linna-Kuosmanen S, Schmauch E, Galani K, Ojanen J, Boix C, Ord T, et al.
Cell Rep Med
. 2024 May;
5(5):101556.
PMID: 38776872
Cardiovascular disease plays a central role in the electrical and structural remodeling of the right atrium, predisposing to arrhythmias, heart failure, and sudden death. Here, we dissect with single-nuclei RNA...
6.
Andreasen L, Neghabat O, Laanmets P, Kumsars I, Bennett J, Olsen N, et al.
JACC Cardiovasc Interv
. 2024 May;
17(9):1106-1115.
PMID: 38749590
Background: Unintended deformation of implanted coronary stents can lead to loss of coronary access, stent thrombosis and coronary events during follow-up. The incidence, mechanisms and clinical outcomes of unintended stent...
7.
Leikas A, Yla-Herttuala S, Hartikainen J
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003709
Adenoviral vectors are commonly used in clinical gene therapy. Apart from oncolytic adenoviruses, vector replication is highly undesired as it may pose a safety risk for the treated patient. Thus,...
8.
Santala O, Lipponen J, Jantti H, Rissanen T, Tarvainen M, Valiaho E, et al.
Cardiol Rev
. 2023 Mar;
32(5):440-447.
PMID: 36946975
Atrial fibrillation (AF) is globally the most common arrhythmia associated with significant morbidity and mortality. It impairs the quality of the patient's life, imposing a remarkable burden on public health,...
9.
Bager J, Martin A, Carbajosa Dalmau J, Simon A, Merino J, Ritz B, et al.
Cardiology
. 2022 Oct;
147(5-6):566-577.
PMID: 36282074
Introduction: Intravenous vernakalant is a therapeutic option for symptomatic, recent-onset atrial fibrillation (AF). This secondary analysis from the large SPECTRUM study assessed the safety and effectiveness of vernakalant when used...
10.
Leikas A, Hassinen I, Kivela A, Hedman A, Mussalo H, Yla-Herttuala S, et al.
J Gene Med
. 2022 Jun;
24(8):e3437.
PMID: 35750637
Background: The phase I KAT301 trial investigated the use of intramyocardial adenoviral vascular endothelial growth factor-D (AdVEGF-D) gene therapy (GT) to alleviate symptoms in refractory angina (RA) patients. In KAT301,...